Abeona therapeutics and taysha gene therapies enter into licensing and inventory purchase agreements for abo-202, a clinical stage, novel, one-time gene therapy for cln1 disease

New york and cleveland and dallas, aug. 17, 2020 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in gene and cell therapy, and taysha gene therapies, a patient-centric gene therapy company with a mission to eradicate monogenic cns disease, today announced that they have entered into license and inventory purchase agreements for abo-202, an adeno-associated virus (aav) gene therapy for cln1 disease (also known as infantile batten disease). the agreements grant taysha worldwide exclusive rights to intellectual property developed by scientists at the university of north carolina at chapel hill (unc) and abeona, and abeona know-how relating to the research, development, and manufacture of abo-202. the therapy was originally developed in the lab of steven gray, ph.d., associate professor at ut southwestern medical center (formerly with unc) and chief scientific advisor for taysha gene therapies. abeona continued to progress the program, including development of the phase 1/2 clinical trial protocol and manufacturing process, and received fda clearance of its investigational new drug (ind) application for a phase 1/2 clinical trial that is anticipated to enter the clinic in 2021.
ABEO Ratings Summary
ABEO Quant Ranking